In 2022, Luo et al. examined the potency of MZ1 and dBET1 (two well-characterized BRD4 degraders that differ only by E3 ligase ligand) across fifty-six cancer cell lines representing ten cancer subtypes [59]. This evidence concerns the gene BRD4 and cancer.